找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2; A Multidisciplinary Siguna Mueller Book 2023 The Editor(s) (if applicabl

[復制鏈接]
查看: 10919|回復: 54
樓主
發(fā)表于 2025-3-21 17:28:35 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2
副標題A Multidisciplinary
編輯Siguna Mueller
視頻videohttp://file.papertrans.cn/224/223419/223419.mp4
概述Analyzes the the risks and benefits of mass vaccination with mRNA vaccines.Covers the most recent scientific data on Covid-19 mRNA vaccines.Offers a broad multidisciplinary look at mRNA vaccines
圖書封面Titlebook: Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2; A Multidisciplinary  Siguna Mueller Book 2023 The Editor(s) (if applicabl
描述.This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first?books to give a comprehensive overview of mRNA vaccines against?COVID-19 and the?only one that addresses this topic from a broad multidisciplinary?background.?It brings together insights?from?various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for?mass vaccination programs enrolled?throughout?the world - focusing on safety and efficacy...This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher?interested?in SARS-CoV2 or virology and vaccine development in general.?.
出版日期Book 2023
關(guān)鍵詞Vaccines; RNA Vaccines; COVID19; mRNA Vaccines; Public Health; Pharmacovigilance; SARS-CoV-2; Corona Virus;
版次1
doihttps://doi.org/10.1007/978-3-031-18903-6
isbn_softcover978-3-031-18905-0
isbn_ebook978-3-031-18903-6
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2影響因子(影響力)




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2影響因子(影響力)學科排名




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2網(wǎng)絡(luò)公開度




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2網(wǎng)絡(luò)公開度學科排名




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2被引頻次




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2被引頻次學科排名




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2年度引用




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2年度引用學科排名




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2讀者反饋




書目名稱Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2讀者反饋學科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:04:40 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:25:01 | 只看該作者
Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2978-3-031-18903-6
地板
發(fā)表于 2025-3-22 07:53:45 | 只看該作者
Siguna MuellerAnalyzes the the risks and benefits of mass vaccination with mRNA vaccines.Covers the most recent scientific data on Covid-19 mRNA vaccines.Offers a broad multidisciplinary look at mRNA vaccines
5#
發(fā)表于 2025-3-22 08:58:31 | 只看該作者
6#
發(fā)表于 2025-3-22 14:54:48 | 只看該作者
7#
發(fā)表于 2025-3-22 17:53:10 | 只看該作者
8#
發(fā)表于 2025-3-22 23:34:45 | 只看該作者
9#
發(fā)表于 2025-3-23 01:22:55 | 只看該作者
Grundlagen der empirischen Untersuchung,ectiveness. Although this is a well-known problem in general, there is no easy solution. Even if one can spend 10 or 15 years assessing a new medical intervention, the problem is still difficult. People respond differently, often expose unexpected biological mechanisms triggered by the intervention,
10#
發(fā)表于 2025-3-23 06:23:45 | 只看該作者
https://doi.org/10.1057/9781403919618alth (PH) officials and decision bodies keep asserting that these vaccines are safe. To those who have experienced adverse events (AEs), or who have close friends or family members who got injured or even passed post-vaccination, this seems incomprehensible. After all, it should be easy to prove tha
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-20 17:41
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
益阳市| 太康县| 乐东| 嘉荫县| 增城市| 阳朔县| 郎溪县| 巴彦淖尔市| 石渠县| 陇川县| 罗平县| 通山县| 双辽市| 旬阳县| 平谷区| 革吉县| 新宁县| 垣曲县| 偃师市| 依兰县| 昌黎县| 涟源市| 汾西县| 罗定市| 宁化县| 云梦县| 华池县| 固安县| 衡南县| 沙雅县| 北川| 视频| 莆田市| 河北区| 界首市| 荥经县| 平山县| 肇东市| 新昌县| 松溪县| 会同县|